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Abstract
Background Vaginal infections are responsible for a large
proportion of gynaecological outpatient visits. Those are
bacterial vaginosis (BV), vulvovaginal candidosis (VVC),
aerobic vaginitis (AV) associated with aerobic bacteria,
and mixed infections. Usual treatments show similar
acceptable short-term efficacy, but frequent recurrences
and increasing microbial resistance are unsolved issues.
Furthermore, vaginal infections are associated with a
variety of serious adverse outcomes in pregnancy and
generally have a major impact on quality of life. Identi-
fying the correct therapy can be challenging for the clini-
cian, particularly in mixed infections.
Findings Dequalinium chloride (DQC) is an anti-micro-
bial antiseptic agent with a broad bactericidal and fungicidal
activity. Systemic absorption after vaginal application of
DQC is very low and systemic effects negligible. Vaginal
DQC (Fluomizinvaginal tablets) has been shown to have
equal clinical efficacy as clindamycin in the treatment of BV.
Its broad antimicrobial activity makes it appropriate for the
treatment of mixed vaginal infections and in case of uncer-
tain diagnosis. Moreover, resistance of pathogens is unlikely
due to itsmultiplemode of action, and vaginalDQCprovides
also a reduced risk for post-treatment vaginal infections.
Conclusions Vaginal DQC (10 mg) as 6-day therapy offers
a safe and effective option for empiric therapy of different
vaginal infections in daily practice. This review summarizes
the available and relevant pharmacological andclinical data for
the therapy of vaginal infections with vaginal DQC and pro-
vides the rationale for its use in daily gynaecologic practice.
Keywords Dequalinium chloride  Vaginal infections 
Vulvovaginal candidosis  Aerobic vaginitis  Vaginal
tablets
Introduction
The human vaginal microbiome is mainly dominated by
lactobacilli, depending on the ethnic background of
women, and consists of probably more than 250 other
different species of bacteria in lower quantities [1, 2].
Although this interactive vaginal ecosystem and its dis-
turbances are not yet fully understood, it is obvious, that it
can change to dysbiosis (disturbed homeostasis or unbal-
anced ecosystem) and demonstrate specific ‘metabolic
signatures’ [3] or can be affected by pathogens causing
infectious diseases. Moreover each woman possess her own
and personal vaginal flora; so any management must con-
sider this individual point of view. Disturbed or abnormal
vaginal flora is divided into vaginal infections which are
localised and affect mainly to the vagina, nevertheless
sometimes disease can spread further to other organs. Most
sexually transmitted infections (STI) belong to this latter
class of diseases. They do often not affect the vagina itself,
but the cervix or the urethra (Chlamydia trachomatis,
Neisseria gonorrhoeae), while Trichomonas vaginalis
involves both urogenital parts. Vaginal dysbiosis or infec-
tions are usually characterised by an abnormal vaginal
discharge and other vaginal signs and symptoms. They can
be differentiated into vaginosis, which does not show
inflammation signs, and vaginitis (usually candidosis or
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aerobic infection), which leads to inflammation. Vaginal
infections and STI are responsible for a large proportion of
gynaecological outpatient visits, from 10 to 20 % of con-
sultations, and are typical in woman of childbearing age.
Further important issues with these vaginal infections are
the very high rate of recurrences and a variety of associated
serious adverse outcomes in pregnancy. Finally, they have
a major impact on the quality of life and driving these
women exhausted.
Although the knowledge about the bacteria- or yeast-
host interactions has increased, there are still open ques-
tions regarding the interactions of vaginal lactobacilli and
pathogens or the role of biofilm [4–6]. It seems that the
local immunity by the vaginal mucosa also plays an
important role. The differential diagnosis of the vaginal
infections is presented in Table 1, Vaginal infections are
highly recurrent and are not only adversely affecting
quality of life but are also associated with a variety of
serious obstetrical and gynaecological complications (pre-
term birth, salpingitis, and many others) [5, 7–9]. Three
main vaginal infections are well defined: (1) bacterial
vaginosis (BV), (2) vulvovaginal candidosis (VVC), and
(3) trichomoniasis/Trichomonas vaginitis (TV). Addition-
ally, there are other vaginal infections which have not yet
been completely characterised and recognised. Especially
the ‘intermediate flora’ (based on Nugent score 4–6) and
the not well defined ‘mixed flora’ or ‘abnormal vaginal
flora’ (AVF) could possibly play a bigger role in the
development of preterm birth than expected before [10].
Moreover, aerobic bacteria are also involved in vaginal
infections but their role is not yet understood. Based on this
knowledge a fourth, still poorly characterised type of
vaginal infections has been defined: aerobic vaginitis (AV)
[11], which is probably the same entity as desquamative
inflammatory vaginitis (DIV), where severe inflammation
is observed and complains are more intense [12, 13].
Additionally, mixed vaginitis (MV) and co-infection with
coexistence of BV, VVC, and TV, is possible [14], and thus
diagnosis and treatment of vaginal infections is not always
easy. This situation can be very challenging for the clini-
cian who has to choose the effective treatment according to
this diagnosis.
Treatment options for vaginal infections remain limited
and the outcome is often unsatisfactory, particularly
regarding the frequent recurrences [15, 16]. This situation
is especially frustrating for women but also for the physi-
cian. The main treatment objectives are the alleviation of
the symptoms, the elimination of pathogens, and eventually
the recovery from disturbed to a healthy lactobacilli-
dominated vaginal flora. Antibiotics exhibit a specific
antimicrobial action which renders them effective drugs for
the treatment of infections. To achieve better long-term
results, every effort should be made to eliminate factors
that predispose an individual to recurrent infection. Main-
tenance-suppressive regimens of antimicrobial agents and
the repetitive application of hydrogen peroxide-producing
lactobacilli to restore and support the healthy vaginal flora
should be considered as treatment options to prevent
recurrences [5, 7, 17–22].
The choice of an anti-infective compound depends on
the type of infection: According to various guidelines,
5-nitroimidazoles (e.g., metronidazole, tinidazole) are used
for the treatment of BV and TV. VVC is treated with orally
or locally administered imidazoles or triazoles (e.g.,
clotrimazole, miconazole, and fluconazole), polyenes or
ciclopiroxolamine. Thus depending on the pathogens
involved, different antimicrobial agents (antibiotics,
antiseptics, antimycotics, etc.) are used as first line therapy,
and controlled trials have shown cure rates of 70–80 %
after 4 weeks of treatment [5, 7, 8, 18, 21–31].
For the treatment of BV, anti-infectives with activity
against anaerobes are indicated, and routine treatment of
sexual partners is usually not recommended [32, 33].
Currently, metronidazole and clindamycin taken orally or
applied vaginally are the mainstays of BV therapy. They
have different spectra of antimicrobial activity but equiv-
alent efficacy with regard to short-term and long-term cure
rates [15, 23, 34–36]. Oral therapy with metronidazole is
usually preferred over vaginal application according to the
various guidelines; however, due to its metabolism in the
liver it is associated with frequent gastro-intestinal side
effects [27, 35, 37–39]. Clindamycin is usually recom-
mended in the form of a vaginal cream. There are several
disadvantages associated with these two therapies [15]: a
significant proportion of patients do not achieve an ade-
quate response [27, 40], recurrence of BV frequently
occurs [23, 27, 38], drug resistance may develop [4, 8, 41–
43], and there is a risk of post-treatment candidosis [38,
44–46].
VVC is usually treated with topical azoles that are avail-
able in a variety of formulations [7, 8, 22, 47]. No evidence
exists to suggest that one azole type or formulation results in
better cure rates. The cure rates for topical azoles are
approximately 80 % [48]. Oral azole formulations also
achieve comparable cure rates; however, they have the
potential of systemic toxicity, sometimes restricting its use.
[7, 8, 22]. Particularly considering recurrence of Candida
infection and azole resistance, treatment with non-azole
agents has its place in practice and might be even more
important in the future [8, 21, 25, 49].
The basis of TV therapy remains the 5-nitroimidazole
group of drugs—metronidazole and tinidazole [7, 8, 49].
Oral therapy is necessary, because infection of the urethra
and periurethral glands provides sources for endogenous
relapses. Cure rates of up to 95 % may be achieved when
sexual partners are treated concomitantly [7, 8, 49].
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Standard treatment for other vaginal infections has not
been established yet. For AV, clindamycin or antibacterial
agents with activity against aerobic gram-positive and -
negative bacteria, such as kanamycin [11, 26, 50, 51] but
also corticosteroids [12] are suggested. Alternatively,
products containing oestrogen alone or in combination with
lactobacilli have been used [52]. For the treatment of MV
[14] drug substances with broad spectrum of antimicrobial
activity are used or a strategy of two-step therapy might be
proposed.
Increasing resistance against metronidazole and clin-
damycin has been reported by several investigators [40, 42,
43, 53]. So far, true acquired antimicrobial resistance
occurring in vaginal infections has not been observed as a
Table 1 Differential diagnosis of vaginal infections [11, 49, 109]
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major problem in clinical practice [27, 54]. Nevertheless,
misuse of the over-the-counter (OTC) antimycotics, as well
as widespread use of systemic oral azoles, could result in
spread of azole-resistant Candida albicans, and even more
likely it could lead to an increase in non-albicans Candida
species with intrinsic azole resistance [54, 55].
In the case of any vaginal infection, the healthy vaginal
microflora is usually disturbed, i.e., the number of lacto-
bacilli is dramatically reduced or less beneficial lactobacilli
such as Lactobacillus iners are dominant, resulting in
unstable vaginal microbiome [56–58]. Following anti-in-
fective treatment, local therapy with beneficial probiotic
lactobacilli is recommended to support long-term restora-
tion of vaginal flora [59, 60]. Repetitive lactobacilli therapy
also has been proposed to normalise the vaginal ecosystem
to prevent the recurrences of vaginal infections, especially
BV [59, 61, 62].
Although antibiotics are selective and effective anti-in-
fectives, it is nevertheless still necessary and desirable to
broaden the therapeutic possibilities [1, 15]. As alternative
therapy broad spectrum antimicrobial agents, such as
dequalinium chloride (DQC), are used to treat vaginal
infections. Typical representatives are phenyl derivates
(e.g., chlorhexidine, hexetidine), acids (e.g., salicylic acid),
halogens (e.g., povidone-iodine), and quaternary ammo-
nium compounds (e.g., DQC). Less specific antimicrobial
agents have the advantage that (1) resistance of pathogenic
microorganisms is not to be expected due to its multiple
mechanism of action [63–66], (2) they can also be used for
mixed vaginal infections because of their broad antimi-
crobial spectrum, as well as additionally (3) for pre- and
post-operative prophylaxis.
The goal of the current article on DQC is to review the
pharmacology and clinical evidence to better understand
this substance and to provide the rationale for its use in
daily clinical practice for the treatment of vaginal
infections.
Pharmacology
Dequalinium chloride (DQC)—1,10-(decane-1,10-diyl) bis
(4-amino-2-methylquinolinium) dichloride—is a bis-qua-
ternary ammonium compound with a broad spectrum
against gram-positive and -negative bacteria, yeasts, and
protozoa [67–70] (Fig. 1).
The antimicrobial activity of DQC and quaternary
ammonium salts in general, is primarily based on their
ability to increase cell permeability with subsequent loss of
enzyme activity [66, 70–72]; the substance exhibits a rapid
bactericidal and fungicidal action [67].
In detail the mechanism of action of DQC is based on
the following mechanisms (Fig. 2):
1. Its effects on bacterial cell permeability are based on
(1) the adsorption on the microorganism’s cell surface
and diffusion through the cell wall, and (2) binding to
the cytoplasmic membrane with subsequent formation
of complexes and protein precipitation [65, 66]. The
cell membrane might be lysed (depending on the
concentration), resulting in perturbed osmotic
exchange.
2. The effects on microbial proteins and metabolic
reactions after diffusion through the cell wall are
caused through (1) denaturation of proteins resulting in
inhibition of bacterial cell metabolism, (2) disruption
of bacterial energy production through inhibition of
glucose metabolism and inhibition of mitochondrial
ATP synthesis via inhibition of bacterial F1-ATPase,
and (3) termination of protein synthesis at the level of
ribosomes [65, 66, 73]. Furthermore effects on bacte-
rial nucleic acids occur such as (1) precipitation of
cytoplasmic material with nucleic acids being the most
sensitive, and (2) binding to DNA (in vitro) [63, 65,
66].
Disruption of cell permeability and subsequent loss of
enzymatic activity is regarded as the primary cause of
bacterial cell death after contact with surface-active com-
pounds [65]. The enzymatic inactivation initially might be
reversible but becomes irreversible after a longer contact
time between DQC and the bacteria. Protein denaturation
and inhibition of metabolic reactions are only obtained at
doses above the clinical use of quaternary ammonium
compounds, and are therefore less relevant for their
antimicrobial action.
The antimicrobial activity of DQC has been investigated
and demonstrated over the past decades by several inves-
tigators [67, 69, 70, 72, 74–80]. An overview of the in vitro
antimicrobial activity of DQC is shown in Table 2, DQC
has a broad antimicrobial activity against all relevant
vaginal pathogens. The bactericidal and fungicidal effect of
DQC has been demonstrated to occur within 30–60 min
[67]. Della Casa and colleagues demonstrated the in vitro
antimicrobial activity of DQC against different pathogens
that are relevant for vaginal infections, including anaerobic
bacteria (Gardnerella vaginalis, Bacteroides spp., Pep-
tostreptococcus spp., etc.), aerobic bacteria (staphylococci,
streptococci, Escherichia coli, etc.), Candida species (C.
albicans, C. glabrata, etc.) and Trichomonas vaginalis
[69]. The antimicrobial activity of DQC against Candida
spp. is comparable with clotrimazole and ciclopiroxo-
lamine [69]. A recent in vitro study has also demonstrated a
high susceptibility of Atopobium vaginae to DQC, and
confirmed that DQC acts bactericidal [80].
No development of resistance of micro-organisms to
DQC has been reported in laboratory studies or clinical
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trials. Resistance of pathogens is unlikely due to the mul-
tiple mode of action of DQC. In fact, multidrug resistance
to single quaternary cationic anti-infectives is associated
rather with hypersensitivity to compounds containing two
quaternary cations, including DQC [81].
For human subjects, published information on quater-
nary ammonium compounds confirms that the blood levels
after oral administration (10–40 mg) are generally low
[82–87]. It is expected that absorption is even lower after
vaginal application [85], supported by the fact that vaginal
application of DQC is very rarely associated with systemic
adverse events as demonstrated in clinical studies. In a
local repeated dose vaginal tolerability study in rabbits,
where daily doses per kg were 2.5–5 times higher than in
clinical use, no DQC was detected in the blood. Absorption
of DQC in rabbits after vaginal application was below
0.625 % of the administered 5 times higher dose/kg, thus
maximum blood levels only in the pg/ml could be expected
after vaginal application of DQC in humans. This is con-
sistent with findings in animal toxicology studies, indicat-
ing that DQC is absorbed to an extremely small degree
(\0.1 %) after oral application [74].
No reproductive toxicity studies have been conducted in
animals because of the anticipated low systemic exposure
to DQC after vaginal administration. Animal studies with
other quaternary ammonium compounds have not shown
embryo-foetal toxicity at clinically relevant doses [84].
Preclinical data indicate that DQC is absorbed only to a
very small degree after vaginal application, i.e., systemic
exposure is negligible [74].
DQC 10 mg vaginal tablet (Fluomizin) has been
developed as a directly compressed vaginal tablet to ensure
Fig. 1 Structure of
dequalinium chloride (DQC)
Fig. 2 Mechanism of action of
dequalinium chloride (DQC)
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fast disintegration of the tablet and rapid dissolution of the
active substance. As soon as the vaginal tablet comes into
contact with the vaginal secretion, the tablet begins to
disintegrate and DQC is released. After dissolution of the
DQC 10 mg tablet in an estimated 2.5–5 ml of vaginal
fluid, the DQC concentration is estimated at
2000–4000 lg/ml, assuming negligible absorption. This
concentration is four to eightfold higher than the minimal
inhibitory concentration (MIC) of the least susceptible
isolate (MIC = 512 lg/ml) [66]. An in vivo anti-infective
effect is generally obtained if the concentration of the
active substance at the site of action is 2–4 times higher
than the MIC for 20 min up to 2 h [69].
The broad spectrum antimicrobial activity covering all
relevant pathogens for vaginal infections and the negli-
gible systemic absorption are the key factors of DQC to
make it suitable for the treatment of most vaginal
infections.
Clinical studies
Local treatment of vaginal infections with DQC is well
established. Various clinical studies published over the last
4 decades demonstrate its good clinical efficacy in different
vaginal formulations [26, 28, 32, 34, 88–106].
The dose tested for the treatment of vaginal infections
ranged from 10 to 50 mg. The immediate release prepa-
rations were used with a strength of 10 and 20 mg DQC,
whereas controlled release preparation contained 20 or
50 mg of DQC. Treatment duration was usually 3–10 days.
The efficacy over the entire dose range was similar and no
difference in tolerability was described [26, 28, 32, 34, 88–
106]. The medicinal products containing DQC which were
tested for vaginal administration in clinical studies are
briefly summarised in Table 3.
Within clinical studies, more than 3000 women with
vaginal infections of different aetiology have been treated
Table 2 In vitro antimicrobial
activity of dequalinium chloride





Gardnerella vaginalis -/? 2–512 256
Atopobium vaginae -/? \0.0625–0.5 0.5




Enterococcus faecalis 1 0.2–64 64
Lactobacillus spp. 1 0.5–8 4
Staphylococcus aureus 1 0.2–8 1.28; 8
Streptococcus agalactiae (group B streptococci) 1 2–64 8; 32
Streptococcus pyogenes (group A streptococci) 1 0.25–20 2
Aerobic gram-negative bacteria
Enterobacter spp. – 3.1–400
Escherichia coli – 1–400 128
Klebsiella spp. – 3.1–400
Pseudomonas spp. – 5–400
Serratia spp. – 3.1–400
Proteus spp. – 20–[1024
Fungi
Candida tropicalis 0.2–50
Candida albicans 0.2–50 1; 8
Candida glabrata 0.2–256 1; 256




Trichomonas vaginalis 28.8–400 57.6
a MICrange: minimum and maximum MIC values for certain species
b MIC90: MIC value at which 90 % of the strains of this species were inhibited
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with vaginal DQC (Table 4). Clinical studies have been
mainly carried out in the treatment of the following vaginal
infections: (1) BV, (2) VVC, (3) less characterised aerobic
and mixed vaginal co-/infections (‘fluor vaginalis’).
Treatment of bacterial vaginosis (BV)
Two recent high quality clinical studies (Weissenbacher
et al. and Petersen et al.) have investigated efficacy and
safety of 10 mg DQC vaginal tablets for treatment of BV—
a total of 212 women have been treated [26, 32].
DQC have been used for a very long time and the first
reference was from 1959. There was no consensus of the
diagnosis of BV at that time. Hence, many older clinical
data should be evaluated with scientific precaution. Nev-
ertheless, additionally some older studies could also pro-
vide some supportive data on clinical efficacy of DQC in
the treatment of vaginal infections which currently could
be described as BV. Within these older clinical studies
(including some unpublished data) a total of 577 women
with more or less well diagnosed BV-like syndromes have
been treated with various vaginal DQC preparations [26,
28, 32, 104, 107].
In a recently published multicentre, controlled study
Weissenbacher and colleagues compared the efficacy of
DQC 10 mg vaginal tablets (Fluomizin) once daily for
6 days to clindamycin vaginal cream 2 % for 7 days in the
treatment of BV [32]. To qualify for inclusion, women had
to be diagnosed with BV, for which all 4 Amsel criteria had
to be present. Follow-up visits were performed at 1 week
and at 4 weeks after the treatment. A total of 321 women
were randomised to receive either 10 mg DQC (n = 164)
or clindamycin (n = 157). The primary efficacy outcome
was clinical cure, where clinical cure was defined as the
absence of clue cells and a negative result for at least 2
other Amsel criteria. Weissenbacher et al. have used the
more than 20 % clue cells criterion: to be cured of BV the
patient could have clue cells present but less than 20 %. At
week 1, clinical cure rates were 81.5 % in women treated
with 10 mg DQC and 78.4 % in clindamycin-treated
women, the difference was not statistically significant. The
treatment of BV with a 6-day course of 10 mg DQC
vaginal tablets had therefore equal efficacy as a 7-day
course of clindamycin vaginal cream. At week 4, the
overall clinical cure rates observed were 79.5 % with
10 mg DQC and 77.6 % with clindamycin, demonstrating
that the efficacy of DQC was as good as clindamycin
(statistically significant) also at long-term follow-up. Most
Amsel criteria were fairly comparable with slight, but
clinically not relevant, differences between the groups. The
total failure rates, including non-responders and BV
recurrences, for the two groups were also comparable. The
number of women with positive cultures of Candida spp.
(‘colonisation’) at week 4 was slightly higher in the clin-
damycin group (14.6 %) than in the DQC group (9.3 %),
however, due to small figures statistically not significant.
Consistent with these results, symptomatic VVC at second
follow-up was half as common with DQC (2.7 %) than
with clindamycin (5.8 %). No serious adverse drug reac-
tions (ADRs) were observed. The proportion of women
reporting ADRs was 17.8 % in the DQC group and 20.3 %
in the clindamycin group. The most frequently reported
reactions in both groups were vaginal discharge followed
by vulvovaginal pruritus.
Petersen et al. [26] in a controlled, randomised, double-
blind, multicentric clinical study compared the efficacy and
safety of 10 mg DQC vaginal tablets (Fluomizin) and
200 mg vaginal povidone iodine in a parallel-group design
[26]. A total of 180 women with vaginal infections of
varying aetiology participated in this study. Women were
randomly allocated to one of the two treatment groups
(DQC—121 and povidone iodine—59) and were treated
Table 3 Medicinal products containing dequalinium chloride (DQC) reported in the treatment of vaginal infections
Medicinal product Formulation References
Dequadin Vaginal pessary 10 mg [88, 95, 99]
Dequavagyn Ovule 50 mg; controlled release for 8–10 days [34, 96]
Dequavagyn Cream 20 mg/10 g cream; controlled release for 8–10 days [34, 91–94, 96, 97, 100]
Oestro-Dequavagyn Cream 20 mg/10 g cream; controlled release for 8–10 days
?0.15 mg estriol/10 g cream
[93, 98]
Oestro-Dequavagyn Cream 20 mg/10 g cream; controlled release for 8–10 days
?2 mg Estriol/10 g cream
[93]
Gyken Ovule 20 mg [28]
Eriosept Vaginal foam 100 mg/100 g [101]
Fluomizin 10 mg vaginal tablet [26, 32]
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once daily for 6 days. The total symptom score was defined
as the overall primary efficacy parameter. Based on this
parameter, the study demonstrated therapeutic equivalence
of vaginal DQC and the reference preparation. In the BV
subgroup a total of 73 women were included, whereof 48
were treated with DQC. Using Amsel criteria, 96 % (after
1 week) and 82 % (after 4 weeks) of patients were cured
after 10 mg DQC therapy. The percentage of women with
positive cultures of G. vaginalis decreased clearly from
60 % before to 7 % after treatment. The improved micro-
bial status was also demonstrated by the increased per-
centage of women with a healthy degree of purity (pure
lactobacilli flora) in the DQC group (at entry—0 %, at
follow-up 1 (after 1 week)—37 %, at follow-up 2 (after
4 weeks)—46 %). The normalisation of the healthy flora
was faster in the DQC group as compared to the reference
group (at entry—0 %, at follow-up 1–14 %, at follow-up
2–50 %).
Strecker and colleagues in a non-controlled clinical
study tested the efficacy and local tolerability of DQC in a
total of 388 women whereof 274 were diagnosed with BV
[28]. Treatment with a vaginally administered 20 mg DQC
ovula (2 ovules daily in a 3 days interval) was successful in
70–85 % of the patients with BV with/without accompa-
nying candidosis and with VVC alone. The therapeutic
efficacy of was rated as good or very good by 91 % of the
patients and by 99 % of the investigators.
Radzinsky and co-investigators [107] presented the
results of a multicentre trial using different therapy regi-
mens in 640 non-pregnant women of reproductive age with
bacterial vaginal infections different aetiology. The trial
was divided into two stages: In the first stage, women
received anti-infective therapy against bacterial vaginosis
or nonspecific vaginitis; afterwards restoration of the
vaginal ecosystem was investigated with probiotic (out-
comes are not described here). In the first stage, women
received vaginal anti-infective treatment at the physician’s
discretion (DQC, clindamycin, chlorhexidine, povidone
iodine, or metronidazole/miconazole combination). In the
group with BV, 409 women positive for BV according to
the Amsel criteria were included in the statistical analysis.
The efficacy of vaginal DQC based on Amsel criteria
(n = 144, 77.8 %) was equivalent to the efficacy of the
other anti-infective therapies (n = 281, 77.1 %).
Overall the clinical studies have demonstrated the
excellent efficacy of 10 mg DQC formulation Fluomizin
in the treatment of BV. Clinical cure rates of 10 mg DQC
were equal to clindamycin 2 % vaginal cream, one of the
current ‘gold standards’ in the treatment of BV. Further-
more, vaginal pH, number of lactobacilli and clinical
symptoms improved clearly during 10 mg DQC therapy;
and additionally DQC demonstrated trend to less cases of
post-treatment VVC than after clindamycin therapy. The
drug was well tolerated; no serious ADRs were observed.
Treatment of vulvovaginal candidosis (VVC)
Dequalinium chloride in different vaginal formulations has
been used to treat a total of 653 women with VVC, and
cure rates were reported between 70 and 90 % [26, 28, 34,
88, 91–94, 96–100].
In a series of clinical studies [34, 91–94, 96, 97, 100],
altogether 490 patients with VVC were treated with a DQC
20 mg depot preparation. In 70–80 % of the cases, patients
were cured. Kolbe [92] reported even a cure rate of 94 %.
In 15–20 % of the cases, symptoms improved and the
microscopic analysis of C. albicans showed a clearly
reduced yeast load. However, in 10–25 % of the cases,
even a repetition of the treatment was not successful [34,
93]. Also in pregnant women with VVC (n = 55), DQC
depot preparation led to complete cure in 84 % of the cases
[91].
Strecker et al. [28] tested a DQC 20 mg vaginal ovula at
day 1 and one ovula at day 4 in women suffering from
VVC with (n = 103): a positive effect—cure or improve-
ment—was demonstrated on more than 90 % of cases.
A DQC 20 mg and estriol combination resulted in total
disappearance of C. albicans in 69 % of the microscopic
evaluated vaginal smears and in considerable reduction of
C. albicans in 19 % of the vaginal smears [98]. In some
studies sexual partners were also parallelly treated with a
DQC vaginal cream (currently commercially not available)
[97, 100]: the cure rate remained at a similar range
77–91 %.
In the earlier mentioned controlled, multicentric clinical
trial, Petersen with collaborators compared the efficacy and
safety of 10 mg DQC vaginal tablets (Fluomizin) and
200 mg vaginal povidone iodine in a parallel-group design
also in women with VVC [26]. Of the total of 180 women,
35 women with VVC (23 women in DQC and 12—in
povidone group) were included, where VVC was diagnosed
by its typical signs and symptoms and by the presence of
yeasts in the wet mounts or in cultures. The clinical
symptoms improved clearly from a total score of 6.5 at
entry to 1.1 at the second follow-up, if treated with DQC.
At entry, all patients (100 %) were positive for Candida
spp. The percentage of positive patients decreased in the
DQC group clearly to 21.7 % at follow-up 1 and 15.8 % at
follow-up 2; the corresponding values in the reference
group were 33.3 and 18.2 %. Global efficacy of DQC at the
end of the study was rated as complete or considerable
improved in 84 and 89 % of cases by investigators and
patients, respectively. DQC therapy was well tolerated with
no serious ADRs observed.
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Treatment in a so far unpublished multicentre drug
utilisation trial by Schmidt has assessed the effectiveness
and tolerability of DQC 10 mg vaginal tablets (Flu-
omizin) in the treatment of ‘acute colpitis’ (vaginal
infections) under conditions of daily practice. In the VVC
group 97 women were included from 30 centres in Ger-
many. Whereas 86.6 % of the women had three or four
symptoms at the entry examination, this was the case for
only 12.2 % at the control examination. The number of
women with Candida-positive culture before therapy was
100 %, and decreased to 20 % after the DQC treatment. No
ADRs were observed.
Overall, different vaginal formulations of DQC in
women with symptomatic VVC in clinical studies
demonstrated similar good efficacy (cure and/or improve-
ment rates) and safety. With the DQC 10 mg vaginal
tablets Fluomizin formulation a total of 120 women (in-
cluding unpublished) with VVC have been treated
demonstrating the high clinical efficacy and tolerability
also for this vaginal formulation [26].
Treatment of less defined vaginal infections
Even though that there are concern that vaginal infections
are also caused by aerobic pathogens, there is still no
consensus of how ‘fluor vaginalis’ should be diagnosed and
it is difficult to compare the results from different inves-
tigators. DQC in different vaginal formulations has been
also used for the treatment of the following less defined
vaginal infections: aerobic bacterial vaginal infections
(AV, AVF, bacterial ‘fluor vaginalis’, etc.), mixed vaginal
infections and co-infections, and Trichomoniasis/TV.
Again, the classification of mixed vaginal infections and/or
co-infections is still purely described. These facts are not
allowing to draw sufficiently clear scientific evaluations
but some general conclusions probably still could be done.
Aerobic bacterial vaginal infections
Within 11 clinical studies, a total of 968 women that have
been diagnosed with this type of vaginal infections were
treated with vaginal DQC [26, 34, 92–94, 96, 97, 99–101,
103, 105, 107]. Roddie [99] has reported treatment results
with DQC 10 mg pessaries twice daily in 30 women with
‘bacterial fluor vaginalis’. Symptoms improved after
2 weeks and resumed in 70 % of the cases after 3 weeks of
treatment. The therapy did not lead to irritation or sensi-
tisation of the vagina.
Different clinical trials reported good results in treat-
ment of ‘bacterial fluor vaginalis’ with a DQC depot
preparation that, once inserted into the vagina, releases
continuously DQC for 8–10 days. A single treatment with
10–20 mg DQC (the precise dose is not mentioned in the
publications) cured 66–76 % of the 137 patients [34, 92–
94, 96, 97, 108].
In the above-mentioned multicentre drug utilisation
trial, Schmidt in an unpublished trial have assessed the
efficacy and safety of DQC 10 mg vaginal tablets in the
treatment of ‘acute colpitis’ (poorly defined vaginal
infections). Totally 213 women were included in the sub-
group of MV (bacterial mixed infection, ‘fluor vaginalis’).
Whereas 62.9 % of the women had three or four symptoms
at the entry examination, this was the case for only 10.0 %
at the follow-up examination. The number of women with
positive cultures for gram-negative and gram-positive
bacteria decreased approximately by 50 %. No ADR was
observed.
Petersen [26] and colleagues includes in their clinical
study also 73 women diagnosed with ‘fluor vaginalis’
(aerobic bacterial vaginal infection), where signs and
symptoms of vaginitis and a disturbed vaginal flora were
present, but BV, VVC and TV were excluded. The total
symptoms score decreased under therapy with DQC from
5.0 ± 1.9 at entry to 1.9 ± 1.5 at follow-up 1 and
1.3 ± 1.3 at follow-up 2. The number of leukocytes ([10
per field of view) decreased in the DQC group for 42.2 %
of patients at entry to 9.3 % at follow-up 1 and 8.6 % at
follow-up 2 (4 weeks). Furthermore, the DQC therapy
resulted in a decrease of the positive cultures for Strepto-
coccus ssp., Enterococcus spp., and E. coli by 36, 49, and
73 %, respectively, at the end of the study.
Radzinsky and colleagues [107] investigated in their
above-mentioned clinical study also the efficacy of vaginal
DQC in 213 women with ‘nonspecific vulvovaginitis’
presenting a clinical picture of an inflammatory and intense
leukocyte reaction ([20 leucocytes field of view in the
vaginal smear, magnification 400 times). The efficacy in
the group of the patients receiving DQC (n = 67) was
estimated above 76 %. The anti-infective efficacy of the
broad spectrum DQC was found to be similar to that of
other most commonly used agents in treating vulvovaginal
infections.
All clinical studies consistently reported a good clinical
efficacy of DQC in the treatment of aerobic bacterial
vaginal infections. This is particularly interesting as for this
pathology no standard treatment has been established yet.
The therapy with vaginal DQC resulted in a clear reduction
of the clinical symptoms, reduction of presence of relevant
facultative-pathogenic microorganisms in vaginal cultures,
and was well tolerated.
Mixed vaginal infections
Clinical studies including women with MV are rare, only
5 published studies report the results of a total of 179
women [28, 92, 93, 98, 100]. Recently Sobel et al. [14]
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described the MV as an infection with at least 2 pathogens
that are well defined. Additionally, it is important to
understand that ‘mixed flora’ and ‘mixed vaginal infec-
tion’ as defined by Sobel could not always be the same
nosologic entity.
After vaginal administration of an DQC ovule 20 mg at
day 1 and one DQC ovule at day 4 to patients suffering
from VVC with BV co-infection (n = 11), approximately
1/3 of the patients showed improvement of symptoms, and
2/3 of the patients were completely cured. These findings
were confirmed by the significant reduction of the vaginal
pH value below 4.5 in approximately 2/3 of the cases.
Furthermore, the positive amine test turned into negative
after the treatment in 87 % of the women with BV co-
infection. Therapy was not successful in only 1/10 of the
cases [28].
The therapy with a combination of DQC (applied dose
not known) with 0.0015 % estriol (Oestro-Dequavagyn)
of 49 women with MV resulted in total disappearance of
the mixed flora in 80 % of the vaginal smears, and in
considerable reduction of the mixed flora in 4 % of the
cases [98].
Trichomoniasis
Within clinical studies, a total of 329 women with TV have
been treated with different vaginal DQC preparations [26,
34, 88, 92–97, 99, 100].
In a series of clinical studies, the efficacy and tolera-
bility of DQC 10 mg pessaries was assessed in altogether
139 trichomoniasis cases. The average treatment lasted
6 weeks and pessaries were applied 1–2 times per day.
Overall, in 40–90 % of the cases T. vaginalis was eradi-
cated and patients were cured, and 10–60 % showed con-
siderable improvement of symptoms [88, 95, 99]. In one
study, treatment was even successful in women who had
previously failed to respond in any satisfactory degree to
any other forms of treatment including the use of pessaries
containing oxytetracycline which today is no first line
medication. However, a number of cases relapsed in a
period of 2–16 weeks after treatment end [100]. The
treatment of trichomoniasis with DQC seems to be less
efficient—the overall efficacy in this disease was reported
17–50 % [34, 96, 97]. In order to achieve complete treat-
ment success concomitant systemic medication with a tri-
chomonacidal agent, for example metronidazole, should be
used [34, 92–94, 100].
Clinical safety
Within clinical studies, different vaginal DQC preparations
have been used to treat more than 3000 women with var-
ious vaginal infections. The overall share of ADRs was
with 2.4 % very low, showing the excellent local tolerance
of vaginally administered DQC. With the DQC 10 mg
vaginal tablets Fluomizin formulation, 1224 women have
been treated in controlled or open clinical studies and only
95 ADRs (7.8 %) were observed and none of them were
serious [26, 32, 102–106]. The majority of the ADRs in
clinical studies (about 90 %) were local reactions, partic-
ularly vaginal discharge, vulvovaginal pruritus, and a
vaginal burning sensation.
Clinical studies in pregnant women
A total of 181 pregnant women have been intentionally
treated with vaginal DQC in four clinical studies, and no
adverse effects on pregnancy or on the health of the foetus/
new-born child (based on pH, Apgar scale, and follow-up
until 1 year) have been observed.
Fauner and Binder [91] treated 55 pregnant women with
VVC by a DQC depot preparation that continuously
releases active substance over 8–10 days. The tolerability
and safety of the treatment was excellent and no ADRs
were reported on pregnant women and new-born.
In an unpublished drug utilisation study, 60 pregnant
women were treated with DQC10 mg. The tolerability of
the treatment was ‘very good’ or ‘good’ for 95 % of the
patients and did not differ from that of the entire group of
patients. No ADRs were reported. Demina and colleagues
[103] investigated the efficacy and safety of DQC vaginal
tablets (Fluomizin) in the treatment of bacterial vaginal
infections during pregnancy. Sixty women in the first tri-
mester of pregnancy at risk for miscarriage and thirty
healthy pregnant women without complications were
included. The latter group of healthy pregnant women
served as reference group. The women at risk for miscar-
riage either received Fluomizin vaginal tablets (group I:
n = 32) or a drug containing povidone iodine (group II:
n = 38). No ADRs were observed. In the DQC group, no
case of spontaneous abortion was observed, whereas in the
povidone iodine group 2 spontaneous abortions were
observed and any treatment by iodine during pregnancy
presents a risk on the foetal iodine metabolism.
Grishchenko et al. [104] treated 34 pregnant women
(week 6–8) suffering from BV with DQC 10 mg vaginal
tablets (Fluomizin) once daily for 6 days. A control group
of 32 pregnant women was treated with povidone iodine.
Following this treatment, the course of the pregnancy, the
pre-natal condition of the foetus and perinatal pathology
were studied. Placental dysfunction in week 16 of preg-
nancy occurred in fewer patients treated with DQC
(29.4 %) than in the control group (84.4 %). The greatest
differences between the groups were found in the amount
of amniotic fluid and placenta maturity. Although the
precise role of BV in pregnancy is still debated, the authors
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concluded that BV is accompanied by the development of
placental dysfunction, causing high levels of pre-natal
foetal hypoxia and perinatal pathology, and the effective
treatment of BV with DQC in the first trimester of preg-
nancy could improve the perinatal outcomes [84, 91, 103,
104].
Summary and conclusions
Vaginal infections are a common medical problem and are
responsible for a large proportion of gynaecological out-
patient visits. These infections are associated with a variety
of serious adverse health outcomes, especially in pregnant
women. The most common vaginal infections are BV and
VVC; however AV/AVF and mixed infections are also
considerably frequent. In clinical practice the correct
diagnosis of vaginal infections, particularly mixed infec-
tions, is often difficult and finding an effective treatment
can be challenging for the clinician.
The main treatment objectives are the alleviation of the
symptoms, the elimination of pathogens, and eventually the
recovery from disturbed to a healthy lactobacilli-dominated
vaginal flora. Additionally high tolerability of the treatment
is needed to increase the compliance and acceptability by
the women. However, treatment options for the vaginal
infections are limited, and the outcome is often unsatis-
factory. Even though current treatments show accept-
able short-term efficacy with cure rates of 70–80 %,
recurrent vaginal infections as well as post-treatment can-
didosis remain an issue.
Acquired microbial resistance and spread of intrinsically
resistant microorganisms as well as bacterial biofilms have
to be considered future challenges for an effective treat-
ment of vaginal infections.
Antibiotics (typically metronidazole and clindamycin)
and antimycotics (azoles) are the most recommended
treatments. In terms of tolerability and safety, vaginal
therapies usually have fewer side effects than oral products.
Increasing resistances and post-treatment vaginal infections
(candidosis after antibacterial therapy, bacterial infections
after antimycotic therapy) also have an impact on the
outcome of the therapy. Due to the risk of vaginal infec-
tions causing serious complications in pregnancy, safe
therapies for pregnant women are also of great importance.
Thus alternative treatments are a key medical need in the
management of vaginal infections.
DQC is an anti-infective agent belonging to the class of
quaternary ammonium compounds. Its broad antimicrobial
activity against all relevant vaginal pathogens is well
established demonstrated by several investigators over the
past decades. DQC exhibits a fast and strong bactericidal
and fungicidal action. The primary mode of action of DQC
is based on an increase in cell permeability with the sub-
sequent loss of enzyme activity. Resistance of pathogens is
unlikely due to its multiple mode of action and has not
been reported. The vaginal application of DQC results in
high local concentration, but due to low absorption sys-
temic exposure is negligible.
In clinical studies described in the literature, medicinal
products with DQC of different concentrations and vaginal
formulations were used. The efficacy over the entire dose
range was similar and no difference in the tolerability was
described. Local treatment of vaginal infections with DQC
is well established, and many publications have demon-
strated its clinical efficacy in different vaginal infections.
Overall, more than 3000 women have been treated with
vaginal DQC in clinical studies for the following vaginal
infections: BV, VVC, AV/AVF, trichomoniasis and mixed
vaginal infections. Independent of the specific DQC drug
used, treatment of vaginal infections of bacterial and
mycotic origin has been shown to result in similarly high
cure rates (70–90 %). Furthermore, a recent clinical study
with DQC also confirmed the comparable efficacy with
clindamycin in the treatment of in BV. The DQC treatment
is a very interesting treatment option for BV but as there
are no long follow-up data available, it would be still
reasonable to perform more clinical studies investigating
cure rates and at least one clinical study with longer follow-
up (6 months).
The safety of DQC has also been demonstrated in these
various clinical studies. No serious ADRs have been
observed. The majority ([90 %) of ADRs were local
reactions (particularly vaginal ulcerations, vaginal dis-
charge, vulvovaginal pruritus, and vaginal burning sensa-
tion) which were mostly mild or moderate in intensity. Due
to the negligible absorption of DQC, systemic events have
been rarely reported. Furthermore, the available clinical
data suggest the suitability of DQC for use during preg-
nancy also. Vaginal DQC is also listed in the German
guideline ‘Bacterial vaginosis’ as well as in the Portuguese
guidelines for treatment of vaginal infections as an effec-
tive treatment for BV [31].
From a clinical point of view DQC could offer an
attractive treatment for vaginal infections, both for BV and
VVC as well as in case of mixed infections—this treatment
concept should be further investigated in broader clinical
studies. Vaginal DQC has been shown to have equal clin-
ical efficacy as clindamycin in the treatment of BV and to
be well tolerated with negligible systemic effects. It has the
major advantage that its broad antimicrobial activity makes
it appropriate for the treatment of mixed vaginal infections
and in case of uncertain diagnosis. Moreover, resistance of
pathogens is unlikely due to its multiple mode of action,
and vaginal DQC provides also a reduced risk for post-
treatment vaginal infections of different aetiology that is
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quite frequent after specific antibacterial or antimycotic
treatment.
In conclusion, the current formulation DQC 10 mg
vaginal tablets (Fluomizin) as 6-day therapy with its
broad antimicrobial spectrum and excellent tolerability
offers a safe and effective option for empiric therapy of
different vaginal infections in daily practice.
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